Initially, this additional benefit of SGLT2 inhibitors appeared to be demonstrated by pooling data from trials testing their efficacy, which were mainly conducted in patients with diabetes mellitus (DM).8,9 Nevertheless, more recently, other meta-analyses found no significant AF prevention with SGLT2 inhibitors.10,11 However, the inclusion of recent trials conducted only in patients with HF may have jeopardized the results of these latter meta-analyses. This evidence concerns the gene SLC5A2 and diabetes mellitus.